The product is in phase-III trials development for the management of breakthrough cancer pain in opioid-tolerant patients.
ProStrakan expects to submit it for marketing approval for Europe in July.
ProStrakan sees Rapinyl – the European rights for which it snaffled from Swedish firm Orexo four months ago – as having the potential to be one of its most important products.
It is a tiny, fast-dissolving, sub-lingual (under the tongue) tablet. It is a formulation of fentanyl, an opioid drug that has been used for many years to manage the sudden surges of pain (referred to as breakthrough pain) often experienced by those with cancer.
The Rapinyl account is being handled by CCA’s med ed arm, Litmus.
The agency, which has never previously worked with ProStrakan, won the business after a pitch against three undisclosed London-based agencies.
An agency to handle UK-specific communications for the product has not been confirmed.
Other agencies used by ProStrakan for comms include Medicom Group and Jago Pearce.